^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CLBR001/SWI019

i
Other names: CLBR001 + SWI019, switchable-CAR-T-cell-therapy, CLBR001/SWI019
Associations
Trials
Company:
AbbVie, Scripps Research Institute
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials